BioCentury | Dec 2, 2020
Distillery Therapeutics

Skeletal muscle-specific derivative of myosin inhibitor tool compound for spasticity and muscle stiffness

DISEASE CATEGORY: Musculoskeletal INDICATION: Spasticity A small molecule inhibitor of fast skeletal muscle myosin isoforms could treat spasticity and muscle stiffness. The compound is a morpholine derivative of blebbistatin, a tool compound inhibitor of multiple...
BioCentury | Nov 20, 2020

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

Olema posts big gain after $209M IPOShares of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) rose $30 (158%) to $49 in their first day of trading after the company raised $209 million through the sale of 11 million...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
BioCentury | Oct 8, 2020

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

Genor’s $371 million IPO on the Hong Kong stock exchange’s prerevenue chapter Wednesday caps a busy 12 months for the Shanghai cancer company during which it has rebooted its C-suite, added dry powder via a...
BioCentury | Oct 2, 2020

C4 is latest preclinical protein degradation IPO with big aftermarket gain

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings.  Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based...
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

NIH in push to improve COVID-19 testing for underserved populationsThe National Institutes of Health has awarded about $234 million to improve COVID-19 testing for underserved and vulnerable populations via the RADx Underserved Populations program. A...
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

Six months after the last round of price cuts for generics and off-patent originator drugs in China’s centralized procurement program, the Chinese government has outlined plans to nearly double the number of included drug formulations....
BioCentury | Jul 23, 2020

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jun 2, 2020

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection by preventing HA-mediated viral entry. The nanoparticles comprise icosahedral bacteriophage capsid proteins conjugated to mono-ethylene glycol-linked sialic acid, which...
Items per page:
1 - 10 of 356